뒤로
Nanjing Leads Biolabs Co., Ltd.(09887.HK) 가격
09887.HK 주가 차트
LEADS BIOLABS-B (09887.HK)
Nanjing Leads Biolabs Co., Ltd.
HK$56.5
2.63%
$1.45
장 종료: Jan 16, 16:00:00 HKT
아직 데이터 없음Follow-Up Questions
Nanjing Leads Biolabs Co., Ltd.의 주요 재무제표는 무엇인가요?
09887.HK의 주요 재무 비율은 무엇인가요?
Nanjing Leads Biolabs Co., Ltd.의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Nanjing Leads Biolabs Co., Ltd.은 수익성이 있나요?
Nanjing Leads Biolabs Co., Ltd.에 부채가 있나요?
Nanjing Leads Biolabs Co., Ltd.의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$55.7
시가
$55.05
일일 범위
$55 - $57.15
52주 범위
$44.72 - $83.6
거래량
260.9K
평균 거래량
590.5K
EPS(TTM)
-1.70
배당수익률
--
시가총액
$8.6B
LEADS BIOLABS-B란 무엇인가요?
Nanjing Leads Biolabs Co., Ltd. operates as a pharmaceutical company. The company is headquartered in Nanjing, Jiangsu and currently employs 192 full-time employees. The company went IPO on 2025-07-25. The Company’s main drug candidates include LBL-024, LBL-034, LBL-033, LBL-007 and others. The firm's LBL-024 is mainly used to treat extra-pulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract carcinoma (BTC), non-small-cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC) and other solid tumors. The firm has also developed multiple proprietary technology platforms, including LeadsBod platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform) and several other bispecific antibody and fusion protein platforms. The firm mainly conducts its business in the domestic market.